GuidelineCanadian journal of gastroenterology = Journal canadien de gastroenterologie2012
An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver.
Guideline in Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 5 syntheses or guidelines pooled it, 144 citations in OpenAlex.
- Treatment for hepatitis C virus-associated mixed cryoglobulinaemia.The Cochrane database of systematic reviews · 2018Pooled it
- The Efficacy and Safety of 12 Weeks of Sofosbuvir and Ledipasvir versus Sofosbuvir, Ledipasvir, and Ribavirin in Patients with Chronic Hepatitis C, Genotype 1, Who Have Cirrhosis and Have Failed Prior Therapy: A Systematic Review and Meta-Analysis.Canadian journal of gastroenterology & hepatology · 2017Pooled it
- Living with Hepatitis C Virus: A Systematic Review and Narrative Synthesis of Qualitative Literature.Canadian journal of gastroenterology & hepatology · 2017Pooled it
- Pooled it
- An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver.Canadian journal of gastroenterology & hepatologyGuideline
- Trends in chronic hepatitis C visits by providers in Quebec, Canada: A population-level cohort study.Canadian liver journal · 2026Article
- Social values for health technology assessment in Canada: a scoping review of hepatitis C screening, diagnosis and treatment.BMC public health · 2020Article
- HCV-infected individuals have higher prevalence of comorbidity and multimorbidity: a retrospective cohort study.BMC infectious diseases · 2019Article
- Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting.Liver international : official journal of the International Association for the Study of the Liver · 2019Article
- The development and validation of magnetic resonance elastography for fibrosis staging in primary sclerosing cholangitis.European radiology · 2019Article
- Real-world health care utilization in treatment of HCV: Results from the Canadian SIMPLE observational trial.Canadian liver journal · 2019Article
- The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2018Article
- Progress in non-invasive detection of liver fibrosis.Cancer biology & medicine · 2018Article
- A Hepatitis C Educational Needs Assessment of Canadian Healthcare Providers.Canadian journal of gastroenterology & hepatology · 2017Article
- Trends in health care utilization and costs attributable to hepatocellular carcinoma, 2002-2009: a population-based cohort study.Current oncology (Toronto, Ont.) · 2016Article
- Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2016Observational
- Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma.World journal of gastroenterology · 2016Review
- CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2016Article
- Hepatitis C virus infection.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2015Article
- Cost-effectiveness of screening for hepatitis C in Canada.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic hepatitis C remains a significant medical and economic burden in Canada, affecting nearly 1% of the population. Since the last consensus conference on the management of chronic hepatitis C, major advances have warranted a review of recommended management approaches for these patients. Specifically, direct-acting antiviral agents with dramatically improved rates of virological clearance compared with standard therapy have been developed, and several single nucleotide polymorphisms associated with an increased probability of spontaneous and treatment-induced viral clearance have been identified. In light of this new evidence, a consensus development conference was held in November 2011; the present document highlights the results of the presentations and discussions surrounding these issues. It reviews the epidemiology of hepatitis C in Canada, preferred diagnostic testing approaches and recommendations for the treatment of chronically infected patients with the newly approved protease inhibitors (boceprevir and telaprevir), including those who have previously failed pegylated interferon and ribavirin therapy. In addition, recommendations are made regarding approaches to reducing the burden of hepatitis C in Canada.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.